Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0050685 |
| Name | small cell carcinoma |
| Definition | A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells. |
| Source | DiseaseOntology.org |
| Alt Ids | DOID:7137 |
| Path | disease disease of cellular proliferation cancer cell type cancer carcinoma small cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01642251 | Phase Ib/II | Cisplatin + Etoposide Veliparib | Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer | Completed | USA | 0 |
| NCT04010357 | Phase II | Abemaciclib | Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC | Active, not recruiting | USA | 0 |
| NCT04209595 | Phase Ib/II | PLX038 + Rucaparib | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | Completed | USA | 0 |
| NCT04429087 | Phase I | BI 764532 | A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 | Recruiting | USA | ESP | DEU | 1 |
| NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
| NCT06464068 | Phase II | Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide Durvalumab | AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA (DURVASCC) | Recruiting | ITA | 0 |
| NCT06788938 | Phase II | Tarlatamab | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | Recruiting | USA | 0 |
| NCT06814496 | Phase Ib/II | Tarlatamab | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) | Recruiting | USA | 0 |
| NCT06889493 | Phase I | Ipilimumab + Nivolumab + SVV-001 | SVV-001 with Nivolumab and Ipilimumab in Patients with Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | Recruiting | USA | 0 |